Sponsored by
Final results from Novocure's Phase 3 METIS trial show that tumor treating fields (TTFields), when used after stereotactic radiosurgery (SRS) for brain metastases from non-small cell lung cancer (NSCLC), significantly delays intracranial progression compared to best supportive care alone. Patients receiving TTFields plus best supportive care had a median time to intracranial progression of 15 months, versus 7.5 months for the control group, with no negative impact on quality of life or neurocognition. For patients who received immune checkpoint inhibitors in addition to TTFields, the benefit was even more pronounced. While overall survival and neurocognitive outcomes were similar between groups, TTFields was well tolerated, with primarily low-grade skin-related side effects. Based on these results, Novocure plans to apply for FDA approval of TTFields for brain metastases from NSCLC.